• Raised $150 million via institutional placement at $3.80 per share
• Placement cornerstoned by new, global long-only institutional investors
• Proceeds to accelerate commercialisation of CT:VQ™ product in the U.S.

4DMedical Limited, a respiratory imaging technology company, has announced that it has received total firm commitments from wholesale, professional and sophisticated investors for a $150 million single-tranche institutional placement at an issue price of $3.80 per share. The capital raise follows rapid commercial traction, with CT:VQ™ deployed at four leading U.S. academic medical centres within four months of FDA clearance, including Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. Proceeds from the capital raise are intended to be used for sales, marketing and business development to drive adoption across U.S. academic medical centres and health systems, customer success and support, research and development, balance sheet flexibility, and general administrative and working capital purposes. The institutional placement was comprised of a $79.1 million placement of new shares and a $70.9 million sale of existing shares on issue. The placement will result in the issue of 20,806,185 shares, representing a 3.86% dilution to existing shareholders. Coincident with the placement, CEO Andreas Fouras and CFO Julian Sutton have exercised options early and increased their respective shareholdings in the Company. The Company will hold an investor webinar on 19 January 2026 to provide further information on the capital raise.